2026 Q1 Portfolio Activity
In 2026 Q1, Rosalind Advisors, Inc. maintained a portfolio of 51 distinct positions. The most significant new addition was VAXCYTE INC, now representing 6.77% of the total fund value. They heavily accumulated shares in XERIS BIOPHARMA HOLDINGS INC, increasing the position by 53.0%. Conversely, Rosalind Advisors, Inc. completely exited their position in REPLIMUNE GROUP INC.
Position History
hover any row below to update
Loading…
Total Positions
51
Quarter
2026 Q1
Top Holding
DCTH (12.3%)
Top 10 Concentration
65.9%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 51
Rosalind Advisors, Inc. Full Holdings List — 2026 Q1
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
DCTH
DELCATH SYSTEMS...
|
Healthcare | 12.31% | 11.60% |
#1
Prev: #1
|
7.0 |
—
|
no change | no change |
P
S
|
3,300,389 | $30,627,610 | 2023 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
XERS
XERIS BIOPHARMA...
|
Healthcare | 7.53% | 5.83% |
#2
2
Prev: #4
|
7.5 |
—
|
1,120,000 | 53.0% |
P
S
|
3,231,700 | $18,743,860 | 2023 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
FENC
FENNEC PHARMACE...
|
Healthcare | 7.19% | 7.07% |
#3
Prev: #3
|
5.9 |
—
|
294,693 | 11.3% |
P
S
|
2,908,201 | $17,885,436 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
SVRA
SAVARA INC
|
Healthcare | 7.03% | 7.21% |
#4
2
Prev: #2
|
3.8 |
—
|
-200,000 | -5.9% |
P
S
|
3,203,721 | $17,492,317 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
PCVX
VAXCYTE INC
|
Healthcare | 6.77% | — |
#5
Prev: #—
|
6.7 |
—
|
290,000 | — |
NEW
|
290,000 | $16,851,900 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
EYPT
EYEPOINT PHARMA...
|
Healthcare | 5.37% | 4.43% |
#6
5
Prev: #11
|
5.1 |
—
|
346,737 | 50.3% |
P
S
|
1,036,737 | $13,363,540 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
XFOR
X4 PHARMACEUTIC...
|
Healthcare | 5.33% | 3.66% |
#7
7
Prev: #14
|
4.6 |
—
|
608,846 | 23.4% |
P
S
|
3,214,766 | $13,276,984 | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
VOR
VOR BIOPHARMA I...
|
Healthcare | 5.02% | — |
#8
Prev: #—
|
5.5 |
—
|
700,000 | — |
NEW
|
700,000 | $12,488,000 | 2024 Q3 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
MDWD
MEDIWOUND LTD
|
Healthcare | 4.85% | 4.86% |
#9
3
Prev: #6
|
2.9 |
—
|
no change | no change |
P
S
|
749,054 | $12,067,260 | 2023 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
VSTM
VERASTEM INC
|
Healthcare | 4.55% | 4.85% |
#10
3
Prev: #7
|
3.8 |
—
|
350,000 | 19.6% |
P
S
|
2,138,475 | $11,333,918 | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
CLDX
CELLDEX THERAPE...
|
Healthcare | 4.21% | — |
#11
Prev: #—
|
5.2 |
—
|
330,000 | — |
NEW
|
330,000 | $10,467,600 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
BCRX
BIOCRYST PHARMA...
|
Healthcare | 3.53% | — |
#12
Prev: #—
|
4.9 |
—
|
923,057 | — |
NEW
|
923,057 | $8,787,503 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
CYBN
CYBIN INC
|
Unknown | 2.95% | 4.77% |
#13
3
Prev: #10
|
1.7 |
—
|
-125,726 | -7.6% |
P
S
|
1,531,814 | $7,352,707 | 2024 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
CGON
CG ONCOLOGY INC
|
Healthcare | 2.72% | 4.38% |
#14
2
Prev: #12
|
1.1 |
—
|
-200,000 | -66.7% |
P
S
|
100,000 | $6,768,000 | 2025 Q2 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
NSPR
INSPIREMD INC
|
Healthcare | 2.56% | 2.44% |
#15
2
Prev: #17
|
2.0 |
—
|
no change | no change |
P
S
|
3,905,743 | $6,366,361 | 2023 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
AVIR
ATEA PHARMACEUT...
|
Healthcare | 2.53% | — |
#16
Prev: #—
|
4.5 |
—
|
1,171,855 | — |
NEW
|
1,171,855 | $6,304,580 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
PROF
PROFOUND MEDICA...
|
Healthcare | 2.16% | 2.96% |
#17
1
Prev: #16
|
0.9 |
—
|
-240,837 | -22.5% |
P
S
|
828,118 | $5,366,205 | 2023 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
VRDN
VIRIDIAN THERAP...
|
Healthcare | 1.97% | 4.92% |
#18
13
Prev: #5
|
0.8 |
—
|
-199,599 | -44.4% |
P
S
|
250,401 | $4,897,844 | 2023 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
N/A
CALL
REPLIMUNE GROUP...
|
|
CALL Option | 1.10% | 0.00% |
#19
19
Prev: #38
|
3.4 |
—
|
1,044,700 | 452.4% |
P
S
|
1,275,600 | $2,746,725 | — | 13F Filing | 2026-03-31 | 2026-05-14 | ||
|
PYPD
POLYPID LTD
|
Healthcare | 1.05% | 1.06% |
#20
3
Prev: #23
|
0.9 |
—
|
-98,630 | -14.2% |
P
S
|
597,926 | $2,618,916 | 2024 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
MYO
MYOMO INC
|
Healthcare | 1.04% | 1.23% |
#21
Prev: #21
|
0.9 |
—
|
7,500 | 0.2% |
P
S
|
3,847,272 | $2,599,217 | 2023 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
TLPH
TALPHERA INC
|
Healthcare | 1.01% | 1.43% |
#22
2
Prev: #20
|
0.9 |
—
|
-225,357 | -6.3% |
P
S
|
3,353,916 | $2,505,040 | 2023 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
OVID
OVID THERAPEUTI...
|
Healthcare | 0.99% | — |
#23
Prev: #—
|
3.9 |
—
|
1,107,994 | — |
NEW
|
1,107,994 | $2,459,747 | 2025 Q2 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
DFTX
DEFINIUM THERAP...
|
Healthcare | 0.95% | — |
#24
Prev: #—
|
3.9 |
—
|
125,000 | — |
NEW
|
125,000 | $2,362,500 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
OKUR
ONKURE THERAPEU...
|
Healthcare | 0.74% | 0.74% |
#25
1
Prev: #24
|
0.3 |
—
|
-286,725 | -39.3% |
P
S
|
443,763 | $1,837,179 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
LPCN
LIPOCINE INC
|
Healthcare | 0.71% | — |
#26
Prev: #—
|
3.8 |
—
|
221,616 | — |
NEW
|
221,616 | $1,770,712 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
NRXS
NEURAXIS INC
|
Healthcare | 0.68% | 0.37% |
#27
4
Prev: #31
|
1.3 |
—
|
no change | no change |
P
S
|
286,138 | $1,693,937 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
AVTX
AVALO THERAPEUT...
|
Healthcare | 0.45% | — |
#28
Prev: #—
|
3.7 |
—
|
75,000 | — |
NEW
|
75,000 | $1,119,750 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
ANNX
ANNEXON INC
|
Healthcare | 0.45% | — |
#29
Prev: #—
|
3.7 |
—
|
200,000 | — |
NEW
|
200,000 | $1,108,000 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
N/A
PUT
INVESCO QQQ TR
|
|
PUT Option | 0.42% | 1.06% |
#30
8
Prev: #22
|
0.2 |
—
|
-200,000 | -44.4% |
P
S
|
250,000 | $1,053,000 | — | 13F Filing | 2026-03-31 | 2026-05-14 | ||
|
AQST
AQUESTIVE THERA...
|
Healthcare | 0.42% | — |
#31
Prev: #—
|
3.7 |
—
|
250,000 | — |
NEW
|
250,000 | $1,037,500 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
N/A
PUT
SPDR S&P 500 ET...
|
|
PUT Option | 0.39% | 0.66% |
#32
7
Prev: #25
|
0.2 |
—
|
-385,000 | -75.5% |
P
S
|
125,000 | $958,500 | — | 13F Filing | 2026-03-31 | 2026-05-14 | ||
|
BFRI
BIOFRONTERA INC
|
Healthcare | 0.38% | 0.23% |
#33
1
Prev: #34
|
0.7 |
—
|
23,198 | 2.0% |
P
S
|
1,163,962 | $941,645 | 2024 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
KURA
KURA ONCOLOGY I...
|
Healthcare | 0.33% | 0.37% |
#34
2
Prev: #32
|
1.1 |
—
|
no change | no change |
P
S
|
100,000 | $813,000 | 2025 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
N/A
REGENTIS BIOMAT...
|
|
Unknown | 0.31% | 0.60% |
#35
8
Prev: #27
|
1.1 |
—
|
no change | no change |
P
S
|
251,510 | $768,363 | — | 13F Filing | 2026-03-31 | 2026-05-14 | ||
|
N/A
PUT
VIRIDIAN THERAP...
|
|
PUT Option | 0.02% | — |
#36
Prev: #—
|
3.5 |
—
|
263,600 | — |
NEW
|
263,600 | $52,720 | — | 13F Filing | 2026-03-31 | 2026-05-14 | ||
|
N/A
CALL
VIKING THERAPEU...
|
|
CALL Option | 0.00% | 0.00% |
Sold All 😨
(Was: #39) |
0.0 |
—
|
-100,000 | -100.0% |
CLOSED
|
— | $— | — | 13F Filing | 2026-03-31 | 2026-05-14 | ||
|
N/A
CALL
UNIQURE NV
|
|
CALL Option | 0.00% | 0.03% |
Sold All 😨
(Was: #37) |
0.0 |
—
|
-100,000 | -100.0% |
CLOSED
|
— | $— | — | 13F Filing | 2026-03-31 | 2026-05-14 | ||
|
N/A
CALL
VERASTEM INC
|
|
CALL Option | 0.00% | 0.06% |
Sold All 😨
(Was: #36) |
0.0 |
—
|
-268,600 | -100.0% |
CLOSED
|
— | $— | — | 13F Filing | 2026-03-31 | 2026-05-14 | ||
|
N/A
CALL
ARRIVENT BIOPHA...
|
|
CALL Option | 0.00% | 0.19% |
Sold All 😨
(Was: #35) |
0.0 |
—
|
-107,900 | -100.0% |
CLOSED
|
— | $— | — | 13F Filing | 2026-03-31 | 2026-05-14 | ||
|
GUTS
FRACTYL HEALTH ...
|
Healthcare | 0.00% | 0.30% |
Sold All 😨
(Was: #33) |
0.0 |
—
|
-385,731 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
N/A
PUT
ISHARES TR
|
|
PUT Option | 0.00% | 0.39% |
Sold All 😨
(Was: #30) |
0.0 |
—
|
-200,000 | -100.0% |
CLOSED
|
— | $— | — | 13F Filing | 2026-03-31 | 2026-05-14 | ||
|
TRVI
TREVI THERAPEUT...
|
Healthcare | 0.00% | 0.44% |
Sold All 😨
(Was: #29) |
0.0 |
—
|
-100,000 | -100.0% |
CLOSED
|
— | $— | 2023 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
N/A
PUT
SPDR SERIES TRU...
|
|
PUT Option | 0.00% | 0.47% |
Sold All 😨
(Was: #28) |
0.0 |
—
|
-1,937,600 | -100.0% |
CLOSED
|
— | $— | — | 13F Filing | 2026-03-31 | 2026-05-14 | ||
|
N/A
PUT
ANAVEX LIFE SCI...
|
|
PUT Option | 0.00% | 0.66% |
Sold All 😨
(Was: #26) |
0.0 |
—
|
-1,168,600 | -100.0% |
CLOSED
|
— | $— | — | 13F Filing | 2026-03-31 | 2026-05-14 | ||
|
AVBP
ARRIVENT BIOPHA...
|
Healthcare | 0.00% | 1.53% |
Sold All 😨
(Was: #19) |
0.0 |
—
|
-215,871 | -100.0% |
CLOSED
|
— | $— | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
OCUL
Ocular Therapeu...
|
Healthcare | 0.00% | 1.71% |
Sold All 😨
(Was: #18) |
0.0 |
—
|
-400,000 | -100.0% |
CLOSED
|
— | $— | 2024 Q2 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
MNMD
MIND MEDICINE M...
|
Unknown | 0.00% | 3.53% |
Sold All 😨
(Was: #15) |
0.0 |
—
|
-750,000 | -100.0% |
CLOSED
|
— | $— | 2025 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
CYTK
CYTOKINETICS IN...
|
Healthcare | 0.00% | 4.36% |
Sold All 😨
(Was: #13) |
0.0 |
—
|
-195,045 | -100.0% |
CLOSED
|
— | $— | 2025 Q2 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
ATYR
ASTRIA THERAPEU...
|
Healthcare | 0.00% | 4.78% |
Sold All 😨
(Was: #9) |
0.0 |
—
|
-1,039,080 | -100.0% |
CLOSED
|
— | $— | 2025 Q3 | 13F Filing | 2026-03-31 | 2026-05-14 |
Showing 1-50 of 51 holdings